



CODEN [USA]: IAJPB

ISSN: 2349-7750

**INDO AMERICAN JOURNAL OF  
PHARMACEUTICAL SCIENCES**<http://doi.org/10.5281/zenodo.1447121>Available online at: <http://www.iajps.com>

Research Article

**STUDY OF IDENTICAL CURATIVE FORMULATION OF  
DIFFERENT BRANDS OF VILDAGLIPTIN**<sup>1</sup>Tahseen Ahmed, <sup>2</sup>Muhammad Shabib Husnain Raza, <sup>3</sup>Dr. Ammara Tariq<sup>1</sup>Department of pharmacy, Shaheed Muhtarma Benazir Bhutto Medical University Larkana.<sup>2</sup>Bahawal Victoria Hospital<sup>3</sup>Medical Officer Khalida Memorial Hospital Sialkot**Abstract:**

*The main objective of the research is to identify the various brands of vildagliptin having identical pharmaceutical formulation. 02 different brands, which were having identical active salt of vildagliptin, were taken for this study and different physicochemical analysis was performed to ensure the quality and therapeutic level. Various test including heaviness distinction, diameter assessment, breadth, crumbling, dissolution, and consequences compared with the standard. All standard took from USP (United States Pharmacopeia). All the parameters were according to the measured or specified standards as mentioned in USP. All parameters for the physicochemical evaluation of vildagliptin tablets of 02 altered brands were performed they were weight variation test, thickness test, diameter test, disintegration test and dissolution. The 02 different variety of vildagliptin salt were having similar curative agent and all results were according to mentioned criteria of USP which was not exceed than  $\pm 1\%$ . Only the time of disintegration was quietly differ but that was not altered the chemical or therapeutic property of that brand.*

**Key words:** Vildagliptin, Weight variation, Dissolution, Disintegration, Pharmacopeia**Corresponding author:****Tahseen Ahmed,**

Department of pharmacy,

Shaheed Muhtarma Benazir Bhutto Medical University,

Larkana.


QR code



Please cite this article in press Tahseen Ahmed et al., *Study of Identical Curative Formulation of Different Brands of Vildagliptin.*, Indo Am. J. P. Sci, 2018; 05(09).

**INTRODUCTION:**

Vildagliptin is the active salt which is used to decrease the hyperglycemic level among diabetic people;<sup>1</sup> it belongs to DPP-4 inhibitors (dipeptidyl peptidase-4) class of anti-diabetic drugs. <sup>2</sup>It is having chemical formula (S)-[(3-Hydroxyadamantan-1-yl) amino] acetyl pyrrolidin-2-carbonitril. Vildagliptin works as secretagogue as it enhances the action the action of pancreases to discharge insulin and also accelerate the working capacity of beta cells.<sup>3</sup> this active salt is having best therapeutic results when it is used alone or in the amalgamation with other anti-diabetic drugs. Low weight gain and very minute episodes of hypoglycemic events is the main quality of vildagliptin, which is observed by the diabetic patients who consume this salt <sup>4</sup>. The main purpose of this research to know the identical curative agents as of vildagliptin brands available in the khairpur city.<sup>5</sup>

Chemical Structure of Vildagliptin<sup>2</sup>**METHODOLOGY:**

**Tablet Specification:** All parameters for the physicochemical evaluation of vildagliptin tablets of 02 altered brands were performed they were weight variation test, thickness test, diameter test, disintegration test and dissolution.

**Weight distinction assessment:** According to standards of the United States Pharmacopeia, there will be no more than 02 tablets out of 20 tablets should exceed the perimeter of  $\pm 7.5\%$  deviation. In the same case the statistical control chart (Shewart chart) shown in table 01. From each marque 20 tablets were assessed on the Electronic Balance and results were resolute that weight of each tablet was according to the standards of USP.

**Breadth Assessment:** Thickness of (vildagliptin) tablets with average, standard deviation, superior and inferior parameters were intended.

**Width Assessments:** Diameter of two numerous products of vildagliptin tablets as well as average, standard deviation, higher and inferior limits were considered.

**Crumbling Test (Disintegration):** Period of disintegration of the both brands were observed and the test was performed on (Curro Model no DS-0702) apparatus. Six tablets from each brand was put in the carrier and roofed with the disk on maintained temperature of 35c' to 39c' using distilled water tablets were not disintegrate than test was repeated on 12 tablets and test was positive and meet the expectation as 16 tablets from 18 tablets were disintegrated and it was clearly mentioned in the USP that tablet should disintegrate within 30 minutes in water for film layered tablets.

**RESULTS:**

Various physicochemical evaluation tests were performed including thickness, weight variation and diameter of two different brands of vildagliptin and the results are mentioned in table number 01.

**TABLE NO 01: Weight (mg), Thickness (mm) and Diameter of 20 tablets of different brands of Vildagliptin**

Tablet	Weight		Thickness		Diameter	
	Vilget	Vildos	Vilget	Vildos	Vilget	Vildos
1	203	226	3.4	4.5	8.1	8.5
2	202	231	3.4	4.5	8.2	8.6
3	199	224	3.4	4.5	8.1	8.5
4	197	225	3.1	4.6	8.1	8.5
5	210	231	3.4	4.6	8.1	8.6
6	199	224	3.3	4.5	8.1	8.6
7	201	226	3.4	4.5	8.1	8.7
8	202	225	3.5	4.6	8.1	8.5
9	198	224	3.1	4.6	8.2	8.5
10	200	226	3.4	4.5	8.2	8.5
11	204	227	3.5	4.5	8.1	8.5
12	206	227	3.5	4.5	8.1	8.5
13	207	226	3.5	4.5	8.1	8.6
14	201	225	3.4	4.5	8.1	8.5
15	204	220	3.4	4.6	8.1	8.5
16	203	223	3.5	4.6	8.1	8.6
17	206	229	3.5	4.6	8.2	8.6
18	204	230	3.5	4.5	8.1	8.5
19	201	227	3.4	4.5	8.1	8.5
20	200	225	3.4	4.5	8.1	8.5

The average weight variation along with its standard deviation was performed and with the use of specific formula the lower limit and upper limit weight was calculated as mentioned in table no 02

**TABLE NO 02: Statistical Weight Variations**

Tablets	Average	Standard Deviation	Upper Limit	Lower Limit
	(mg)		(X+3S)	(X-3S)
Vilget	202.1	2.57	209.81	194.38
Vildos	231.35	2.34	238.38	224.31

After analysis of weight of all tablets individually the compression was made with the standard as described in USP and all the tablets of two different brands meet with the specification as mentioned in table no 03

**Table No 03: Weight Variation Test**

Tablets	Results (mg)	USP Specification	Deviation from USP Specifications
Vilget	202.1	Deviation should be $\pm 7\%$	Within the specified Limit
Vildos	231.35	Deviation should be $\pm 7\%$	

The same criteria was repeated with the thickness test and result were compared with the standard as mentioned in United States of Pharmacopeia (USP) and all the results were under given range as in table 04

**Table No 04: Statistical Thickness**

Tablet	Average	Standard Deviation	Upper Limit	Lower Limit
	(mm)		( $\bar{X}+3S$ )	( $\bar{X}-3S$ )
Vilget	3.425	0.04426	3.55778	3.29222
Vildos	4.505	0.022361	4.57208204	4.43791796

The same test was again performed for the diameter of each tablet of two different brands and lower and upper limit was also calculated with application of standard deviation formula as mentioned in table no 05

**Table No 05: Statistical Diameter**

Tablet	Average	Standard Deviation	Upper Limit	Lower Limit
	(mm)		( $\bar{X}+3S$ )	( $\bar{X}-3S$ )
Vilget	8.16	0.05	8.31	8.00
Vildos	8.57	0.04	8.71	8.42

after physical test of weight variation, thickness and diameter the in vitro test for dissolution and disintegration was also performed and results were matched with the standard as described in USP and time was noted for all tablets as given in table no 06

**Table No 06: Disintegration Test**

Tablet	Disintegration Time	Limits	Deviation from USP
Vilget	4 min 22 sec	NMT 30 Min	Pass
Vildos	2 min 45 sec	NMT 30 Min	Pass

**DISCUSSION:**

The motive of this research to analyze the standards of 02 altered products of vildagliptin pills. All physicochemical parameters including weight distinction, breadth, and diameter and crumbling test were performed on two different brands of vildagliptin. The result of weight variation test was according to the standards of USP and meets the requirement as mentioned in tables below. Thickness of all pills of vildagliptin such as Standard deviation, average mass, greater and lesser parameters were in accord with the standards of United States Pharmacopeia as shown in Table. Diameter of all pills of vildagliptin tablets such as standard deviation, average weight, higher and lesser limits were also the specification of USP as mentioned in table 05. Disintegration time was also observed for the both brands of vildagliptin tablets, Vilget (Brand) crumbled in 4 min and 22 sec whereas Vildos (Brand) disintegrate in 2 min and 45 sec. The results and

limits were according to the standards as mentioned in USP and data is specified in table 06.

**CONCLUSION:**

The 02 different variety of vildagliptin salt were having similar curative agent and all results were according to mentioned criteria of USP which was not exceed than  $\pm 1\%$ . Only the time of disintegration was quietly differ but that was not altered the chemical or therapeutic property of that brand.

**REFERENCES:**

1. Chantal Mathieu and Evy Degrande Vildagliptin: a new oral treatment for type 2 diabetes mellitus Vasc Health Risk Manag. Dec; 4(6): 1349-1360
2. Kleppinger EL, Helms K. The Role of vildagliptin in the management of type 2 diabetes mellitus. Ann Pharmacother, 2007; 41:824-32.
3. Corelia B Landersdorfer, Yan-Ling He and

William J Jusko Mechanism-based population pharmacokinetics modelling in diabetes: Vildagliptin as a tight binding inhibitor and substance of dipeptidyl peptidase IV Br J Clin Pharmacol. 2012 Mar;73(3):391-401

4. Ahren B, Foley JE, Bosi E, Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. *Diabetes Obes Metab.* 2011; 13:193-203
5. Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycemic risk compared with glimpiride, with no weight gain: results from a 2-year study. *Diabetes obes Metab.* 2010; 12:780-789
6. Keating GM, Vildagliptin: A review of its use in type-2 diabetes mellitus. *Drugs.* 2010; 70:2089-2112.
7. Fonseca V, Baron M, Shao Q, Dejager S. sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. *Horm Metab. Res.* 2008;40:427-430.